Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Patients taking Novo Nordisk’s anti-obesity jab sustained weight loss for up to four years and had a ...
LONDON - Patients taking Novo Nordisk’s Wegovy obesity treatment maintained an average of 10 per cent weight loss after four years, potentially boosting the drugmaker’s case to insurers and ...
The Laxxon weight loss tablet under the product identifier "LXM.2" is designed to provide patients with a non-invasive once-a ...
Those with the genetic variants associated with a "hungry gut" lost an average of 14.4% of their body weight after nine months. Given Wegovy's high cost, these genetic markers could be used to ...
(Reuters) - Certain genes may identify patients with obesity who are most likely to respond strongly to Novo Nordisk's weight ...